Find where your beauty brand isblurring focus.
Scan any beauty or personal-care site through the NES framework. See whether the founder story, ingredient claims, before-and-after copy, and reviews tab work together, or whether the brand is stretching past where its claim base can support it.
“It flagged where our clinical-style claims had drifted from the evidence behind them. Compliance noticed before we did.”
Brand director, skincare
Where the claim stretches past the proof.
Beauty sites live on claims, and the gap between the claim and the proof is where the brand quietly loses trust. The scan surfaces that gap before a regulator, retailer, or buyer does.
Are efficacy, clinical, and ingredient claims framed where their evidence sits?
Does the homepage, PDP, founder story, and reviews tab tell the same brand?
Is the brand speaking to one buyer, or splitting across age, skin concern, and lifestyle?
Does the clinical tone on About match the editorial tone on the campaign pages?
Has the brand widened across skincare, body, and makeup without the story tightening?
Does the premium voice match how the product is actually packaged and delivered?
Three uses inside beauty.
Before a relaunch, retailer review, or claim refresh. The structured read sharpens what the team is allowed to say.
Before a campaign or category extension. Surfaces the friction before more spend lands on top.
Before a client engagement. Quoted-evidence diagnosis that the founder team and the compliance team can both read.
This is not a website opinion. It is a brand consistency diagnosis.
Most AI website audits give broad suggestions: improve the headline, add testimonials, clarify the CTA. The Brand Consistency Scanner is powered by the Net Entropy Score framework, a diagnostic system built to identify where a brand's message, proof, audience, claims, trust signals, and customer promise start drifting apart.
| Generic AI website prompt | NES Brand Consistency Scanner |
|---|---|
| Gives general website feedback | Uses a structured NES diagnostic framework |
| Depends on how good your prompt is | Built around fixed consistency dimensions |
| Often says "improve headline / add proof" | Shows identity confusion, trust leakage, and clarity gaps |
| One-off opinion | Repeatable score and report structure |
| Website-only opinion | Connects to review-inferred and measured customer consistency tiers |
| Hard to compare across brands | Built for competitor comparison and tracking |
Powered by the Net Entropy Score framework. This scan applies NES scoring logic to detect message clarity, identity confusion, trust leakage, brand consistency, and diagnostic confidence.
Same engine. Beauty-tuned read.
Free scan is the website layer. Deeper tiers add written analysis, customer-voice across portals, and measured cohort data.
Fast website-only scan. Surfaces visible clarity, trust, identity, and message gaps in about two minutes.
Human-reviewed deeper read. Claim-vs-proof map, founder-to-PDP coherence, voice analysis with quoted evidence and direction.
Customer language across Sephora, Ulta, Amazon, Reddit, and beauty forums. Shows the gap between site promise and lived product experience.
Customer-verified consistency measurement using structured cohort survey and the v4.0 NES instrument. Defensible to a board or investor.
Net Entropy Score (NES) v1.0. Working paper: SSRN Abstract 6667158. This Website-Based Brand Consistency Scan is AI-assisted and derived from public website signal pattern recognition on the submitted pages only. Outputs are directional estimates calibrated to the NES framework, not precision forecasts or professional advice. AI systems can make mistakes, miss context, or misinterpret public information. NES, Impossible Marketing, and affiliated operators are not liable for decisions, losses, or actions taken based on this scan. Use this report to open questions and guide further diligence, not as the sole basis for business, investment, legal, financial, or operational decisions. This scan is not a regulatory or claim-substantiation review. Claim review must remain the responsibility of qualified clinical and regulatory counsel.